A government decree that defines new rules for compilation of reimbursable drug lists entered into force on September 1 of 2014. This white paper prepared in association with Aston Group looks into this complex system and the consequences of the decree.
The decree is meant to accomplish two important things: unify the existing lists and introduce the transparent criteria for inclusion of essential medicines in them (the bulk of public drug procurement in Russia is based on the nomenclature of pharmaceutical products specified in the respective lists).
The key to understanding the government policy with regards to drug lists lies in the fact that the universal drug reimbursement system has not been established unequivocally in this country. Whatever is termed as drug reimbursement today covers just a small number of those who seek medical attention. According to the current arrangements, only the selected categories of outpatients with specific conditions are entitled to free or discounted medicines (as part of the so called drug reimbursement programs).
*Please note: this is an excerpt of the full article. To read the article in its entirety, please click the ‘download full article’ button at the bottom of the page.
To read more about this new list, what it means for reimbursement and access in Russia, and the challenges that remain ahead in its full implementation, download the full article.
Aston Consulting today offers state-of-the-art technologies and reliable data for efficient and innovative business solutions. Among our customers are drug manufacturers, pharmacy chains, medical and patient communities, government agencies, and professional associations operating in the health care market.
